Tango Therapeutics, Inc.
Tango Therapeutics (Nasdaq: TNGX) is a precision oncology company that discovers and develops small-molecule medicines for cancers defined by genetic alterations or biomarkers. Its programs use targeted approaches, including synthetic lethality, to inhibit cancer-cell vulnerabilities while seeking to spare normal… From the company’s description.
Over the twelve months to Jun 30, 2026, Tango Therapeutics, Inc. reported revenue of $53.81M, up 121.5% from a year earlier, and a net loss of $123.72M. Its operating margin was −253.4%, and operations used $143.90M in cash. In fiscal 2025, it reported revenue of $62.38M, up 48.3% from fiscal 2024, and a net loss of $101.59M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tango Therapeutics, Inc. does
In the company’s own words
Tango Therapeutics (Nasdaq: TNGX) is a precision oncology company that discovers and develops small-molecule medicines for cancers defined by genetic alterations or biomarkers. Its programs use targeted approaches, including synthetic lethality, to inhibit cancer-cell vulnerabilities while seeking to spare normal cells. The company’s clinical-stage portfolio includes vopimetostat, an MTAP-deletion-selective PRMT5 inhibitor being studied as a single agent and with RAS inhibitors, and brain-penetrant PRMT5 inhibitor TNG456, focused on central nervous system cancers such as glioblastoma. Other programs include TNG260, a CoREST inhibitor being studied in STK11-mutant, KRAS-wild-type lung cancer, and TNG961, a development candidate targeting HBS1L in FOCAD-deleted/MTAP-deleted cancers. Tango has no approved products and generates no product-sales revenue; it relies on external manufacturers for investigational drug production and conducts development through clinical trials and collaborations, including with Revolution Medicines, Erasca and Eli Lilly. The company was formed through a 2021 merger involving BCTG Acquisition Corp., previously a special purpose acquisition company. Its website is http://www.tangotx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1819133
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tango Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tango Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tango Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tango Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tango Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”